| P50 | author | Ulrich Kruse | Q114724373 |
| | Gerard Drewes | Q28323684 |
| | Carsten Hopf | Q51502942 |
| | Marcus Bantscheff | Q57196241 |
| P2860 | cites work | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells | Q21735929 |
| | A probability-based approach for high-throughput protein phosphorylation analysis and site localization | Q21735934 |
| | Quantitative proteomic assessment of very early cellular signaling events | Q57979684 |
| | The Hallmarks of Cancer | Q221226 |
| | Phosphoproteomic Analysis of the Mouse Brain Cytosol Reveals a Predominance of Protein Phosphorylation in Regions of Intrinsic Sequence Disorder | Q22061729 |
| | A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling | Q24294449 |
| | Large-scale characterization of HeLa cell nuclear phosphoproteins | Q24300834 |
| | ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage | Q24306743 |
| | Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells | Q24338435 |
| | Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry | Q24561920 |
| | 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease | Q24606651 |
| | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 |
| | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 |
| | Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors | Q24649799 |
| | Accurate quantitation of protein expression and site-specific phosphorylation | Q24671013 |
| | Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS | Q24680943 |
| | The utility of ETD mass spectrometry in proteomic analysis | Q24682151 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Global, in vivo, and site-specific phosphorylation dynamics in signaling networks | Q27864128 |
| | Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics | Q28131742 |
| | Large-scale analysis of the yeast proteome by multidimensional protein identification technology | Q28131778 |
| | Quantitative analysis of complex protein mixtures using isotope-coded affinity tags | Q28145324 |
| | Quantitative proteomic analysis of post-translational modifications of human histones | Q28235630 |
| | Multidimensional separations-based shotgun proteomics | Q28237501 |
| | Quantitative mass spectrometry in proteomics: a critical review | Q28238800 |
| | Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules | Q28256069 |
| | Ion mobility-mass spectrometry | Q28264959 |
| | Quantitative proteomics using stable isotope labeling with amino acids in cell culture | Q28271745 |
| | Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics | Q28277407 |
| | Phosphoproteomic analysis of the developing mouse brain | Q28280338 |
| | Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry | Q28280900 |
| | Mass spectrometry-based proteomics turns quantitative | Q28291379 |
| | Can we rationally design promiscuous drugs? | Q28294268 |
| | High-throughput phosphotyrosine profiling using SH2 domains | Q28307390 |
| | Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry | Q36816844 |
| | Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. | Q36857947 |
| | Pathway proteomics and chemical proteomics team up in drug discovery. | Q36863059 |
| | Accurate mass measurements in proteomics. | Q36890553 |
| | Methods, algorithms and tools in computational proteomics: a practical point of view | Q36912285 |
| | Activity-based protein profiling for the functional annotation of enzymes | Q36954380 |
| | Signal transduction by growth factor receptors: signaling in an instant | Q37000318 |
| | Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review | Q37096042 |
| | Advances in the analysis of protein phosphorylation. | Q37104843 |
| | Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins | Q37108016 |
| | Activity-based protein profiling: from enzyme chemistry to proteomic chemistry | Q37119021 |
| | High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS. | Q37183087 |
| | Experimental and computational approaches to quantitative proteomics: status quo and outlook | Q37187047 |
| | Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned? | Q37204224 |
| | Affinity separation and enrichment methods in proteomic analysis | Q37213417 |
| | FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway | Q39042319 |
| | Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. | Q40013753 |
| | Highly robust, automated, and sensitive online TiO2-based phosphoproteomics applied to study endogenous phosphorylation in Drosophila melanogaster. | Q40045831 |
| | Differential expression of novel tyrosine kinase substrates during breast cancer development | Q40080993 |
| | Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia | Q40237297 |
| | Graded regulation of the Kv2.1 potassium channel by variable phosphorylation. | Q40242350 |
| | Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry | Q40268142 |
| | Structural bioinformatics-based design of selective, irreversible kinase inhibitors | Q40307105 |
| | Activity-based probes that target diverse cysteine protease families | Q40330849 |
| | Analysis of drug-induced effect patterns to link structure and side effects of medicines | Q40363457 |
| | Discovery of novel targets of quinoline drugs in the human purine binding proteome | Q41916662 |
| | Phosphoproteome analysis of Drosophila melanogaster embryos | Q42199723 |
| | Fractionation of isotopically labeled peptides in quantitative proteomics | Q43808104 |
| | On the iTRAQ of kinase inhibitors | Q44919797 |
| | The blood peptidome: a higher dimension of information content for cancer biomarker discovery | Q44924621 |
| | Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors | Q46139047 |
| | Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry | Q46482170 |
| | Stable isotope labeling by amino acids in cell culture (SILAC) and proteome quantitation of mouse embryonic stem cells to a depth of 5,111 proteins | Q46876645 |
| | Top-down quantitation and characterization of SILAC-labeled proteins | Q46963081 |
| | Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. | Q51913136 |
| | Unique scanning capabilities of a new hybrid linear ion trap mass spectrometer (Q TRAP) used for high sensitivity proteomics applications. | Q53741073 |
| | Multiple Reaction Monitoring to Identify Sites of Protein Phosphorylation with High Sensitivity | Q57011006 |
| | Reproducible isolation of distinct, overlapping segments of the phosphoproteome | Q57205837 |
| | Fast LC separation of a myoglobin digest: a case study using monolithic and particulate RP 18 silica capillary columns | Q57346434 |
| | Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research | Q57830708 |
| | A model for random sampling and estimation of relative protein abundance in shotgun proteomics | Q29547316 |
| | Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents | Q29547450 |
| | Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 |
| | Epidermal growth factor receptor mutations in lung cancer | Q29615474 |
| | The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 |
| | Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus | Q30691672 |
| | Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards | Q30759842 |
| | Use of proteomic patterns in serum to identify ovarian cancer | Q30819686 |
| | Analysis and validation of proteomic data generated by tandem mass spectrometry | Q31131394 |
| | Discovering potent and selective reversible inhibitors of enzymes in complex proteomes | Q31141832 |
| | Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. | Q33235253 |
| | Proteomics in clinical trials and practice: present uses and future promise | Q33245305 |
| | Cancer cell-based genomic and small molecule screens | Q33266186 |
| | A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways | Q33266917 |
| | iTRAQ reagent-based quantitative proteomic analysis on a linear ion trap mass spectrometer | Q33300715 |
| | Highly efficient peptide separations in proteomics Part 1. Unidimensional high performance liquid chromatography | Q33305766 |
| | Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy | Q33318685 |
| | Affinity as a tool in life science | Q33333933 |
| | Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. | Q33756854 |
| | Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors | Q34005966 |
| | Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS | Q34192662 |
| | Tyrosine phosphoproteomics of fibroblast growth factor signaling: a role for insulin receptor substrate-4. | Q34341785 |
| | Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. | Q34388251 |
| | Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation | Q34423535 |
| | Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins | Q34473545 |
| | A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies | Q34507101 |
| | Identification of the ligands of protein interaction domains through a functional approach. | Q34584256 |
| | Update on epidermal growth factor receptor mutations in non-small cell lung cancer | Q34594740 |
| | Functional interrogation of the kinome using nucleotide acyl phosphates | Q34599227 |
| | Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome | Q34635360 |
| | Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma | Q34655394 |
| | Chronic myeloid leukaemia | Q34657509 |
| | Higher-energy C-trap dissociation for peptide modification analysis. | Q34667664 |
| | Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags | Q34756963 |
| | Issues and progress with protein kinase inhibitors for cancer treatment | Q35096214 |
| | Proteomic applications for the early detection of cancer | Q35097366 |
| | Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants | Q35221149 |
| | Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications | Q35610017 |
| | Activity-based probes for proteomic profiling of histone deacetylase complexes | Q35611605 |
| | Large-scale phosphorylation analysis of mouse liver | Q35616333 |
| | Regulation of the c-Abl and Bcr-Abl tyrosine kinases | Q35621355 |
| | Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. | Q35629586 |
| | Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks | Q35749545 |
| | Defective downregulation of receptor tyrosine kinases in cancer | Q35824123 |
| | From magic bullets to designed multiple ligands | Q35848618 |
| | A common phosphotyrosine signature for the Bcr-Abl kinase | Q35849758 |
| | Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update | Q36066038 |
| | Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. | Q36109012 |
| | Phosphoinositide 3-kinases as drug targets in cancer | Q36166811 |
| | Developing liquid chromatography ion mobility mass spectometry techniques | Q36227955 |
| | Characterisation of kinase-selective inhibitors by chemical proteomics | Q36273850 |
| | Profiling of UV-induced ATM/ATR signaling pathways. | Q36288898 |
| | Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 |
| | Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting | Q36390245 |
| | Signaling networks assembled by oncogenic EGFR and c-Met | Q36392991 |
| | Accessible proteomics space and its implications for peak capacity for zero-, one- and two-dimensional separations coupled with FT-ICR and TOF mass spectrometry | Q36421814 |
| | Chemoproteomics-driven drug discovery: addressing high attrition rates | Q36483941 |
| | Dissection of the insulin signaling pathway via quantitative phosphoproteomics | Q36497303 |
| | The purinome, a complex mix of drug and toxicity targets | Q36536315 |
| | HPLC techniques for proteomics analysis--a short overview of latest developments. | Q36662326 |
| | Tagging and detection strategies for activity-based proteomics. | Q36686285 |
| | Histone deacetylase inhibitors: biology and mechanism of action | Q36803706 |
| P433 | issue | 10 | |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 1887-1901 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care | |
| P478 | volume | 7 | |